86 related articles for article (PubMed ID: 9551957)
21. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue.
Murakami T; Eda Y; Nakasone T; Ami Y; Someya K; Yoshino N; Kaizu M; Izumi Y; Matsui H; Shinohara K; Yamamoto N; Honda M
AIDS; 2009 Jul; 23(12):1485-94. PubMed ID: 19528788
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
[TBL] [Abstract][Full Text] [Related]
23. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.
Parren PW; Ditzel HJ; Gulizia RJ; Binley JM; Barbas CF; Burton DR; Mosier DE
AIDS; 1995 Jun; 9(6):F1-6. PubMed ID: 7662189
[TBL] [Abstract][Full Text] [Related]
24. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
[TBL] [Abstract][Full Text] [Related]
25. Primary Th1 cell immunization against HIVgp160 in SCID-hu mice coengrafted with peripheral blood lymphocytes and skin.
Delhem N; Hadida F; Gorochov G; Carpentier F; de Cavel JP; Andréani JF; Autran B; Cesbron JY
J Immunol; 1998 Aug; 161(4):2060-9. PubMed ID: 9712080
[TBL] [Abstract][Full Text] [Related]
26. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates.
Haynes BF; Ma B; Montefiori DC; Wrin T; Petropoulos CJ; Sutherland LL; Scearce RM; Denton C; Xia SM; Korber BT; Liao HX
Virology; 2006 Feb; 345(1):44-55. PubMed ID: 16242749
[TBL] [Abstract][Full Text] [Related]
27. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
28. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
29. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
[TBL] [Abstract][Full Text] [Related]
30. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus.
Chamat S; Walsh EE; Anderson D; Osta M; Awaraji C; Pan LZ; Ochi J; Shuey S; Brams P
J Infect Dis; 1999 Aug; 180(2):268-77. PubMed ID: 10395839
[TBL] [Abstract][Full Text] [Related]
31. Involvement of the complement system in antibody-mediated post-exposure protection against human immunodeficiency virus type 1.
Gauduin MC; Weir R; Fung MS; Koup RA
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):205-11. PubMed ID: 9491910
[TBL] [Abstract][Full Text] [Related]
32. Localization of HIV-1 in human thymic implant in SCID-hu mice after intravenous inoculation.
Ogura A; Noguchi Y; Yamamoto Y; Shibata S; Asano T; Okamoto Y; Honda M
Int J Exp Pathol; 1996 Oct; 77(5):201-6. PubMed ID: 8977371
[TBL] [Abstract][Full Text] [Related]
33. Viral pathogenesis in hu-PBL-SCID mice.
Mosier DE
Semin Immunol; 1996 Aug; 8(4):255-62. PubMed ID: 8883149
[TBL] [Abstract][Full Text] [Related]
34. Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1.
Kollmann TR; Pettoello-Mantovani M; Zhuang X; Kim A; Hachamovitch M; Smarnworawong P; Rubinstein A; Goldstein H
J Exp Med; 1994 Feb; 179(2):513-22. PubMed ID: 8294863
[TBL] [Abstract][Full Text] [Related]
35. Virolysis and in vitro neutralization of HIV-1 by humanized monoclonal antibody hNM-01.
Nakamura M; Terada M; Sasaki H; Kamada M; Ohno T
Hybridoma; 2000 Dec; 19(6):427-34. PubMed ID: 11152394
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.
Stoddart CA; Galkina SA; Joshi P; Kosikova G; Long BR; Maidji E; Moreno ME; Rivera JM; Sanford UR; Sloan B; Cieplak W; Wrin T; Chan-Hui PY
Virology; 2014 Aug; 462-463():115-25. PubMed ID: 24971704
[TBL] [Abstract][Full Text] [Related]
37. Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.
Gauduin MC; Safrit JT; Weir R; Fung MS; Koup RA
J Infect Dis; 1995 May; 171(5):1203-9. PubMed ID: 7751695
[TBL] [Abstract][Full Text] [Related]
38. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.
Dadachova E; Patel MC; Toussi S; Apostolidis C; Morgenstern A; Brechbiel MW; Gorny MK; Zolla-Pazner S; Casadevall A; Goldstein H
PLoS Med; 2006 Nov; 3(11):e427. PubMed ID: 17090209
[TBL] [Abstract][Full Text] [Related]
39. Preparation and maintenance of SCID-hu mice for HIV research.
Bristol GC; Gao LY; Zack JA
Methods; 1997 Aug; 12(4):343-7. PubMed ID: 9245615
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.
Joseph A; Zheng JH; Chen K; Dutta M; Chen C; Stiegler G; Kunert R; Follenzi A; Goldstein H
J Virol; 2010 Jul; 84(13):6645-53. PubMed ID: 20410262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
